For more information please visit: www.pathfindercelltherapy.com.
SyntheMed is a biomaterials company focused on the development and commercialization of anti-adhesion and drug delivery products, and other surgical implants. The Company's research and development initiatives encompass a broad range of bioresorbable polymeric compositions which blend both hydrophilic and hydrophobic components. For more information about SyntheMed please visit: www.synthemed.com.
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements or predictions, including statements regarding the potential closing of the merger and the timing thereof, the characteristics and possible uses of the product candidates of each of Pathfinder and SyntheMed and the potential benefits or value to SyntheMed's stockholders of the merger. Actual results may differ materially from these statements. For risks associated with the merger and Pathfinder, please see SyntheMed's definitive proxy statement filed with the SEC on July 26, 2011. For risks associated with SyntheMed's business, please see SyntheMed's Form 10-K filed with the SEC on March 25, 2011.
For more information, please contact:
Executive Chairmain, SyntheMed, Inc.
President and CEO, Pathfinder Cell Therapy, Inc.
|SOURCE SyntheMed, Inc.|
Copyright©2010 PR Newswire.
All rights reserved